Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “SSTR-expressing Tumors”

23 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 23 results

Testing effectiveness (Phase 2)Study completedNCT01237457
What this trial is testing

177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

Who this might be right for
Neuroendocrine Tumors
Ebrahim S Delpassand 143
Testing effectiveness (Phase 2)WithdrawnNCT04276597
What this trial is testing

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

Who this might be right for
Pulmonary Neuroendocrine NeoplasmPheochromocytomaParaganglioma+7 more
Excel Diagnostics and Nuclear Oncology Center
Not applicableStudy completedNCT02810600
What this trial is testing

Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors

Who this might be right for
Neuroendocrine Tumors
Centre de recherche du Centre hospitalier universitaire de Sherbrooke 2,120
Not applicableNot Yet RecruitingNCT07621146
What this trial is testing

A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies

Who this might be right for
Neuroendocrine Tumors, NETPheochromocytoma/ParagangliomaSSTR-expressing Tumors+1 more
British Columbia Cancer Agency 51
Not applicableNo Longer AvailableNCT02174679
What this trial is testing

68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)

Who this might be right for
Carcinoid CancerNeuroendocrine TumorsMedullary Thyroid Cancer+1 more
Jonsson Comprehensive Cancer Center
Large-scale testing (Phase 3)Study completedNCT00442533
What this trial is testing

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Radio Isotope Therapy of America 200
Testing effectiveness (Phase 2)Ended earlyNCT03773133
What this trial is testing

Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)

Who this might be right for
Small Cell Lung Cancer and Breast Cancer
Ipsen 9
Not applicableApproved For MarketingNCT04334837
What this trial is testing

Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)

Who this might be right for
Neuroendocrine Tumors
Curium US LLC
Early research (Phase 1)Study completedNCT00964756
What this trial is testing

An Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers

Who this might be right for
Ovarian Cancer
University of Alabama at Birmingham 11
Testing effectiveness (Phase 2)Active Not RecruitingNCT06590857
What this trial is testing

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Who this might be right for
Metastatic Breast CancerHER2-negative Breast CancerER+ Breast Cancer+7 more
RayzeBio, Inc. 16
Testing effectiveness (Phase 2)Looking for participantsNCT07129252
What this trial is testing

Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Who this might be right for
SST2-positive Neuroendocrine NeoplasmsNeuroendocrine TumorsNeuroendocrine Neoplasm
Crinetics Pharmaceuticals Inc. 150
Early research (Phase 1)Active Not RecruitingNCT05595460
What this trial is testing

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

Who this might be right for
SCLC,Extensive Stage
RayzeBio, Inc. 21
Early research (Phase 1)WithdrawnNCT06411301
What this trial is testing

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors

Who this might be right for
Multiple Myeloma, RefractoryMultiple Myeloma in RelapseMultiple Myeloma Progression
Jules Bordet Institute
Testing effectiveness (Phase 2)Looking for participantsNCT06840821
What this trial is testing

Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors

Who this might be right for
Advanced Solid Tumors
Mainline Biosciences (Shanghai) Co., Ltd 156
Testing effectiveness (Phase 2)Looking for participantsNCT06607692
What this trial is testing

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Who this might be right for
Solid Tumor CancerMedulloblastomaHigh Risk Neuroblastoma+19 more
Fundación de investigación HM 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT05153772
What this trial is testing

Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients

Who this might be right for
Neuroendocrine Tumors
Orano Med LLC 69
Testing effectiveness (Phase 2)Looking for participantsNCT06456359
What this trial is testing

Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

Who this might be right for
Desmoplastic Small Round Cell TumorSynovial Sarcoma
University Hospital Heidelberg 28
Testing effectiveness (Phase 2)Study completedNCT00006370
What this trial is testing

Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer

Who this might be right for
Breast CancerLung Cancer
Novartis Pharmaceuticals 275
Early research (Phase 1)Looking for participantsNCT07165132
What this trial is testing

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Who this might be right for
GEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor Disease+6 more
RayzeBio, Inc. 104
Early research (Phase 1)Study completedNCT03966651
What this trial is testing

A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.

Who this might be right for
Neuroblastoma
Institut Claudius Regaud 1
Next Page